News NICE recommends Afinitor, Xalkori, as cancer drug review con... NICE has recommended two cancer drugs, as it continues its review of treatments in the old Cancer Drugs Fund.
News Novartis' LEE011 on fast track to challenge Ibrance US regulator grants fast review for breast cancer drug.
News GSK settles US bribery probe for $20m Actions of Chinese subsidiaries violated US bribery laws, says SEC.
Views & Analysis Astellas wins first Real-World Evidence prize at UK awards UK awards first to introduce a real-world evidence category.
News Pfizer's breast cancer drug step closer to EU approval Ibrance is already Pfizer's top oncology product.
Patients Making direct-to-patient work, with Matt Wadyka Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
